Skip to main content
OpenTrials
Completed

NCT Number: NCT04417400

Evaluation of Medicines Use Review in Slovenia

Medicines Use Review service (PUZ) has been officially introduced in Slovenian pharmacy practice in 2015 and has been offered to pharmacy customers by pharmacist, certified to provide the service. Patients can to talk to a pharmacist and discuss their medicines, how they use it and any issues or question they might have. We designed a study to evaluate how Medicines Use Review (PUZ) work and how it is reaching the set objectives. The objectives of the PUZ service are to address actual patient medicines use and consequently improve medication adherence, identify and solve drug related problems and enhance medication knowledge. Pharmacists, who are certified to provide the service, recognized the patients, who might need the service and invited them to participate in the study. The study consisted of two visits in 12 weeks' time period. Patients, who decided to participate, were randomly allocated in two groups - intervention and control. Both groups were interviewed and fulfilled questionnaires at visit 1 (V1). Afterwards the test group patients received PUZ. After 12 weeks both groups attended the visit 2 (V2), where they were re-interviewed and fulfilled questionnaires again. After the study completion also the patients from control group received PUZ due to ethical reasons.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medicines Use Review Service Adherence, Medication Behavior Health Behavior Medication Adherence Multiple Medication Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Community pharmacy "Lekarna Brežice", Brežice, Slovenia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • at least one prescription medicine for a chronic condition for at least six months
  • deemed to be suitable for MUR by a pharmacist, certified to provide the MUR service;
  • ability to communicate in Slovenian; The inclusion of patients was performed in accordance with the SOP MUR, to reflect how patients are generally offered MUR service in Slovenia.

Exclusion criteria

  • urgent need of MUR (the service delay due to randomization would risk their health);
  • referred for MUR by a healthcare professional (general practitioner, nurse, etc.);
  • the patient's carer, rather than the patient themselves, was able to attend the interviews and receive MUR;
  • previously received MUR or an advanced medication review;
  • difficulties understanding, communicating or other issues (vision, hearing) that might affect study outcomes.

Treatment and study plan

medicines use review

Behavioral

The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).

Primary outcomes

  1. medication adherence

    Time frame: 12 weeks (V2-V1)

    Self-reported medication adherence to multiple medications, evaluated by an 8-item Morisky Medication Adherence Scale (©MMAS-8) and scored with ©Morisky Widget MMAS-8 Software. MUR impact was defined as the relative difference in in MMAS-8 score after 12 weeks (V2-V1) between test and control group.

Secondary outcomes

  1. drug-related problems

    Time frame: 12 weeks (V2-V1)

    The changes in the proportion of manifested DRPs, the proportion of patients with at least one mDRPs, and the risk of the mDRPs between visits. This outcome only considered for the intervention group (test group), therefore the before-after analysis was applied.

  2. Medicine-associated burden

    Time frame: 12 weeks (V1-V2)

    MUR impact on medicine-associated burden was defined as the mean relative difference in the score of Living with Medicines Questionnaire (©LMQ), visual analog scale (VAS) and each domain score between test and control group after 12 weeks (V1-V2).

  3. Patient information ('knowledge') regarding medicines

    Time frame: 12 weeks

    Interview with the patients. Patients answered three questions regarding each of their regularly used prescription medicines: (i) "What are you taking the medicine for?", to state the purpose of medicine use; (ii) "How are you supposed to take the medicine?", to state the daily dose; and (iii) "Do you know of any special warnings regarding the medicine? If yes, which ones?". Accuracy of answers regarding the purpose of medicine and its daily dose were checked by comparing them with either physician instructions or, when physician instructions were unavailable, Summary of Product Characteristics (SmPC). Answers were deemed to be 'correct' if they matched the information in these sources, 'incorrect' if they did not match or 'not known' if patients responded with "I don't know" or 'no'. Proportions of correct and incorrect answers per patient-medicine, and proportions of improvement or deterioration in given information between visits for the test and control group, were assessed.

Sponsors and collaborators

Lead sponsor

Mitja Kos

Other

Collaborators

  • Comunity pharmacy Celjske lekarne
  • Comunity pharmacy Gorenjske lekarne
  • Comunity pharmacy Goriška lekarna Nova Gorica
  • Comunity pharmacy Javni zdravstveni zavod Mariborske lekarne Maribor
  • Comunity pharmacy Kraške lekarne Ilirska Bistrica
  • Comunity pharmacy Lekarna Brežice
  • Comunity pharmacy Lekarna Kočevje
  • Comunity pharmacy Lekarna Ljubljana
  • Comunity pharmacy Lekarna Ormož
  • Comunity pharmacy Lekarna Sevnica
  • Comunity pharmacy Lekarne Ptuj
  • Comunity pharmacy Obalne lekarne Koper
  • Comunity pharmacy Pomurske lekarne Murska Sobota
  • Comunity pharmacy Žalske lekarne Žalec

Registry information

Official study title

Benefits of Medicines Use Review Service in Slovenia: a Randomized Controlled Trial

Acronym: SLOPUZ

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jun 4, 2020
Registry last updated
Jun 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.